-patients were a source of C. difficile transmission, although they accounted for less onward transmission than TS + /FT + cases. Although transmission from symptomatic patients with either fecal toxin status accounted for a low overall proportion of new cases, both groups should be infection control targets.
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Clostridium difficile infection (CDI) remains a significant concern for patients and healthcare providers, despite recent falls in incidence in some settings, including the United Kingdom [1] . Three UK studies using whole-genome sequencing (WGS) have shown, in endemic settings with routine infection control policies, that only a minority of cases are acquired from other known cases: 35% of cases in Oxford [2] and Leeds [3] and 37% of ribotype 027 cases in Liverpool [4] were genetically linked to a previous case. Only a subset of these cases also shared time on the same hospital ward. Studies using other genotyping techniques have found similar results [5] [6] [7] . Such findings question the sources of C. difficile responsible for most CDIs. While hospitalized asymptomatically colonized patients are a potential source [7] [8] [9] , another group of patients with enhanced potential to transmit C. difficile is symptomatic patients who are toxigenic strain positive (TS + ), but fecal toxin negative (FT -). These patients are identified by 2-step algorithms for CDI diagnosis [10] . An initial screen (eg, glutamate dehydrogenase [GDH] enzyme immunoassay [EIA], or toxin gene nucleic acid amplification test [NAAT] ) detects the presence of C. difficile; the second confirmatory step detects fecal toxin using either EIA or a cell cytotoxin assay (CCT). In the United Kingdom, TS + /FT -patients are usually regarded as being colonized with C. difficile but not infected, based on a large multicenter prospective study showing that only patients with detectable fecal toxin had adverse outcomes [11] . However, outside the United Kingdom, such patients, typically identified with NAATs, are often [12] , but not universally [13] , regarded as having CDI, and NAAT testing has been recommended in some guidelines [14] . were cultured as described previously [15] and whole-genome sequenced using Illumina technology. In Leeds, isolates were confirmed as C. difficile with matrix-assisted laser desorption/ionization time-of-flight-mass spectrometry; in Oxford WGS was used. Sequences were mapped to the 630 reference genome [16] , and assembled de novo [17] (see Supplementary Methods for details). Multilocus sequence types (STs) [15] , were determined in silico.
Toxigenic strains were identified using BLAST searches of de novo assemblies (≥1000 nucleotide identities with toxin A or B genes). Nontoxigenic strains were excluded (n = 249), and the most common STs were ST15 (n = 66 origin was determined using standard surveillance definitions [18] . Cases were defined as healthcare-associated if sampled >48 hours after admission or discharged within ≤4 weeks, as indeterminate if discharged 4-12 weeks previously, and as community-associated if discharged >12 weeks prior to sampling, or without any hospital admission.
Analysis
Single-nucleotide polymorphisms (SNPs) between sequences were determined from maximum likelihood phylogenies constructed with phyML [19] after correction for recombination with ClonalFrameML [20] . Sequences related to a previous sequence within ≤2 SNPs were considered consistent with plausible direct transmission; ≤2 SNPs is expected between transmitted strains obtained ≤123 days apart [2] . Results for sequences related to previous sequences within varying thresholds (0-10 SNPs) were generated as a sensitivity analysis. In patients with multiple samples, sequences >10 SNPs different to a previous sequence from the same patient were considered to represent acquisition of a new strain; 10 SNPs is considerably more variation than would be expected from within-host diversity and mutation over the 1-year study period [2] . Patients with toxigenic C. difficile who shared time on the same ward following the diagnosis of the first patient and before the diagnosis of the second were considered to have had ward contact. Patients admitted to the same ward, but up to 28 days apart, were considered related by possible ward contamination if the first patient was diagnosed before their ward discharge, and the second patient following their admission to the same ward [5] . Patients who shared time in the same hospital, but had no ward or ward contamination contact, were considered to have hospital contact. A sensitivity analysis assumed ward contamination persisted for 365 days.
Logistic only 6% also shared a hospital ward at the same time or within 28 days, and only 10% had any form of hospital contact. This supports previous WGS-based studies, at both our hospitals [2, 3] and others [4] , that found that only a minority of CDIs are acquired from other cases in endemic settings. The proportion in the present study is lower than the 35%-37% identified previously. The most likely explanation is the very small number of infections with the epidemic ST1 (027/NAP1) strain, reflecting falling UK incidence [22, 23] and the burden of transmissions attributable to ST1 in previous studies [3] . Our study has several limitations. Only patients with diarrhea were sampled, and at the discretion of individual practitioners. However, the ratio of toxin-positive stools sequenced to samples tested was 3.6% (289/8068) in Leeds, and 4.6% (218/4704) in Oxford, suggesting that rates of testing were high, including compared with the UK average from 2008 of 6.45%, when testing was principally based on toxin detection [24] . Of those tested, some patients with C. difficile will have been missed by the GDH assay (sensitivity, 92.3%-97.1% [11, 25] assessment of the duration of detectable C. difficile. Our study was performed in a setting where the majority of CDI arises from a diverse range of endemic strains; findings may vary in higher-incidence settings, including where the epidemic ST1 (027/NAP1) strain dominates. Despite these limitations, we demonstrate that patients with toxigenic C. difficile without detected fecal toxin account for a quarter or more of potential within hospital transmission events from symptomatic patients. More intensive infection control interventions around such cases, including routine isolation, should be considered to mitigate transmission risk. Compared with asymptomatically colonized patients, TS + /FT -patients represent a good initial target for expanding infection control efforts, as they are less numerous, and, as discussed above, appear to be more infectious [21] on a per-patient basis. However, ultimately if the findings of Longtin et al [9] can be replicated, isolation of asymptomatically colonized patients, who are each less infectious but more numerous, may result in greater reductions in transmission. Substantially greater resource requirements limit the later approach. Some GDH + fecal toxin-negative patients may carry nontoxigenic C. difficile and not pose an infection control risk. Patients with toxigenic C. difficile could be identified by screening with a toxin gene NAAT, or using a 3-step strategy (GDH + /FT -samples tested with a toxin gene NAAT).
The results of this and previous studies in both Oxford and Leeds suggest CDI cases, and also symptomatic patients with toxigenic C. difficile with a negative fecal toxin result, are not sources for the majority of CDIs. Major unanswered questions remain, including what proportion of CDI cases can be explained by healthcare-associated and community contact with asymptomatically colonized people, and the extent to which other possible sources including food [26, 27] and the environment [28] contribute to CDI. In addition to reducing the risk of CDI through antimicrobial stewardship [23] , understanding the relative importance of each of these reservoirs across a range of settings is required to develop rational control polices and reduce the incidence of CDI. Meanwhile, efforts to reduce hospital transmission from symptomatic patients with toxigenic C. difficile with a negative fecal toxin result should be implemented.
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